Cadegiani: An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial [Spironolactone]

An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial

Cadegiani et al., medRxiv, doi:10.1101/2020.10.05.20206870 (Preprint)

Cadegiani et al., An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological.., medRxiv, doi:10.1101/2020.10.05.20206870 (Preprint)

Oct 2020 Source PDF

Twitter
Facebook

All Studies Meta

Prospective study of 270 female COVID-19 patients in Brazil, 75 with hyperandrogenism, of which 8 were on spironolactone. Results suggest that HA patients may be at increased risk, and that spironolactone use may reduce the risk compared to both other HA patients and non-HA patients. SOC included other treatments and there was no mortality or hospitalization. This study is excluded in the after exclusion results of meta analysis: significant unadjusted differences between groups.

Important missing comments or errors? Let us know.

recovery time, 76.7% lower, relative time 0.23, p = 0.006, treatment 8, control 262, excluding anosmia.

recovery time, 82.8% lower, relative time 0.17, p = 0.002, treatment 8, control 262, including anosmia.

time to viral-, 37.9% lower, relative time 0.62, p = 0.02, treatment 8, control 262.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Cadegiani et al., 6 Oct 2020, prospective, Brazil, preprint, 4 authors, average treatment delay 3.0 days.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Spironolactone All

An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial

MD, MSc Flavio A Cadegiani, Andy Goren, Carlos G Wambier, John Mccoy

doi:10.1101/2020.10.05.20206870

Background: While COVID-19 remains largely unclear and mortality continues to raise, early effective approaches prior to complications lack, as well as researches for characterization and therapeutical potential options in actual early COVID-19. Although females seem to be less affected than females, hyperandrogenic (HA) phenotype, like polycystic ovary syndrome (PCOS), idiopathic hirsutism, congenital adrenal hyperplasia (CAH) female androgenetic alopecia (AGA), or idiopathic HA may be at higher risk due to its inherent enhanced androgenic activity. The present study aimed to evaluate the effects of any early pharmacological approach to females diagnosed with COVID-19 .

References

Cadegiani, Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?, Am J Physiol Endocrinol Metab, doi:10.1152/ajpendo.00136.2020

Cadegiani, Goren, Wambier, Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS), Med Hypotheses, doi:10.1016/j.mehy.2020.110112

Cadegiani, Repurposing existing drugs for COVID-19: an endocrinology perspective, BMC Endocr Disord, doi:10.1186/s12902-020-00626-0

Cadegiani, Wambier, Goren, Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19

Cavalcanti, Zampieri, Rosa, Azevedo, Veiga et al., Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19, N Engl J Med, doi:10.1056/NEJMoa2019014

Clauw, Häuser, Cohen, Fitzcharles, Considering the potential for an increase in chronic pain after the COVID-19 pandemic, Pain, doi:10.1097/j.pain.0000000000001950

Goren, Mccoy, Wambier, What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy

Goren, Vano-Galvan, Wambier, A preliminary observation: male pattern hair loss among hospitalized COVID-19 patients in Spain -A potential clue to the role of androgens in COVID-19 severity

Goren, Wambier, Herrera, Mccoy, Vaño-Galván et al., Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men, J Eur Acad Dermatol Venereol, doi:10.1111/jdv.16953

Guan, Ni, Hu, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med

Hajifathalian, Kumar, Newberry, Obesity is associated with worse outcomes in COVID-19: Analysis of Early Data From New York City, Obesity, doi:10.1002/oby.22923

Kalligeros, Shehadeh, Mylona, Association of Obesity with Disease Severity among Patients with COVID-19, Obesity, doi:10.1002/oby.22859

Kim, Kim, Ra, Lee, Bae et al., Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19, Clin Microbiol Infect, doi:10.1016/j.cmi.2020.04.040

Kragholm, Andersen, Gerds, Association between male sex and outcomes of Coronavirus Disease 2019 (Covid-19) -a Danish nationwide, register-based study, Clin Infect Dis

Lauer, Grantz, Bi, The Incubation Period of Coronavirus Disease

Lechien, Chiesa-Estomba, Siati, Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study, Eur Arch Otorhinolaryngol, doi:10.1007/s00405-020-05965-1

Mccoy, Wambier, Herrera, Vaño-Galván, Gioia et al., Androgen Receptor Genetic Variant Predicts COVID-19 Disease Severity: A Prospective Longitudinal Study of Hospitalized COVID-19 Male Patients, J Eur Acad Dermatol Venereol

Novak, Post COVID-19 syndrome associated with orthostatic cerebral hypoperfusion syndrome, small fiber neuropathy and benefit of immunotherapy: a case report, eNeurologicalSci, doi:10.1016/j.ensci.2020.100276

Palaiodimos, Kokkinidis, Li, Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, Metabolism

Pascarella, Strumia, Piliego, Bruno, Buono et al., COVID-19 diagnosis and management: a comprehensive review, J Intern Med, doi:10.1111/joim.13091

Stokes, Zambrano, Anderson, Coronavirus Disease 2019 Case Surveillance -United States, January 22, MMWR Morb Mortal Wkly Rep

Tong, Wong, Zhu, Fastenberg, Tham, The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Metaanalysis, Otolaryngol Head Neck Surg, doi:10.1177/0194599820926473

Wu, Chen, Cai, Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan

Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit